Denali Therapeutics, Inc.
(NASDAQ : DNLI)

( )
DNLI PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.41%202.721.3%$426.59m
BIIBBiogen Inc.
-2.46%220.061.3%$391.11m
GILDGilead Sciences, Inc.
-0.49%64.910.9%$378.65m
CELGCelgene Corporation
1.13%102.951.3%$367.47m
ILMNIllumina, Inc.
-0.36%309.443.5%$247.45m
REGNRegeneron Pharmaceuticals, Inc.
-0.46%300.192.6%$218.58m
EXASExact Sciences Corporation
-0.95%96.4724.1%$199.33m
VRTXVertex Pharmaceuticals Incorporated
-0.84%176.231.9%$176.44m
ALXNAlexion Pharmaceuticals, Inc.
-1.58%98.412.0%$169.95m
AAgilent Technologies, Inc.
-0.44%74.591.6%$143.57m
SRPTSarepta Therapeutics, Inc.
-1.91%85.7714.6%$132.47m
BMRNBioMarin Pharmaceutical Inc.
1.84%69.154.3%$96.30m
SGENSeattle Genetics, Inc.
1.70%87.406.2%$95.18m
NKTRNektar Therapeutics
-2.81%17.275.5%$84.77m
ALDRAlder Biopharmaceuticals, Inc.
0.11%18.9210.2%$81.63m

Company Profile

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.